# NAD+: Reliably Raised, Not Yet Proven to Matter > NAD+: Research Overview — British Colombia Peptides — A cited literature summary of NAD+ and its precursors NMN and NR: redox-coenzyme mechanism, human dose-response trials, and why raising blood NAD+ has not yet been shown to translate into hard clinical outcomes. **04 / RESEARCH PEPTIDE FUNDAMENTALS** The cell's central redox coenzyme, and the honest gap between raising its blood level and demonstrating a clinical benefit from doing so. **NAD+ code reference** NAD+: 20% for a first order, 15% for any order - `GRANT` — 20% off your first order (New customers only. First order.) - `GRANT15` — 15% off any order (No minimum. Applies to repeat orders.) ![Oath Research NAD+, sold as research material at oathresearch.com](https://oathresearch.com/wp-content/uploads/2025/08/NJ500-2-768x768.png) *Both codes are current. Applying either one makes no payment to this site.* ## The short version NAD+ (nicotinamide adenine dinucleotide) is a molecule every cell in the body needs to make energy and repair DNA. Levels fall with age, which is the reason a supplement industry has grown around raising it back up using precursor molecules — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — since plain oral NAD+ itself is poorly absorbed intact. Human trials of these precursors consistently raise blood NAD+ levels in a dose-dependent way, and some show secondary improvements like better walking distance or muscle insulin sensitivity in specific groups [19][20]. What they have not yet done is establish that raising NAD+ changes a hard clinical outcome — disease risk, longevity, organ function — at the population level. A 2025 review of the human evidence is explicit about this gap: age-related NAD+ decline has been consistently observed in only a limited number of human studies, and tissue-specific NAD+ data remain sparse [18]. ## What it is NAD+ is a dinucleotide — two linked nucleotide units, one built from nicotinamide (a form of vitamin B3) and one from adenosine — with the molecular formula C21H27N7O14P2. It exists in two interconverting forms: an oxidized form (NAD+) and a reduced form (NADH), and the ratio between them is a running readout of a cell's metabolic state. Because NAD+ itself does not cross into cells efficiently when taken orally, most supplement and research interest has shifted to its precursors, NMN and NR, which the body converts into NAD+ internally. ## How it works NAD+ has two jobs. First, it is the cell's central redox carrier, shuttling electrons through glycolysis, the citric-acid cycle and the mitochondrial electron transport chain to generate ATP, the cell's energy currency. Second, it is a consumed substrate — not just a catalyst — for several signaling enzyme families: sirtuins (which regulate gene expression and metabolism), PARPs (central to DNA-damage repair), and CD38, an enzyme that both consumes NAD+ and rises with age and inflammation. That rising CD38 activity is the leading explanation for why NAD+ availability falls as people get older, and it is the mechanistic rationale for precursor supplementation [21]. ## What the research shows *NMN dose-response (multicenter RCT).* In a double-blind, placebo-controlled trial in healthy middle-aged adults, oral NMN at 300-900 mg/day for 60 days dose-dependently raised blood NAD+, with significant increases at both 30 and 60 days across all NMN groups versus placebo (p≤0.001). The 600 mg/day dose was identified as optimal, walking distance improved, and no safety issues emerged at any dose tested [19]. *NMN and insulin sensitivity.* In prediabetic, postmenopausal women, 10 weeks of oral NMN at 250 mg/day significantly improved muscle insulin sensitivity, measured by the clamp method considered the gold standard for this outcome — though body composition and HbA1c did not change [20]. *NR dose-response.* In healthy overweight adults, NR at 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively, in a clean dose-response relationship, with no flushing and no meaningful difference in adverse events from placebo at any dose. NR also did not raise LDL cholesterol or disrupt related metabolic pathways [22]. *The 2025 synthesis.* A narrative review of the human clinical evidence on NAD+ precursor supplementation in aging concluded that, despite the consistent blood-level findings above, human trials to date show limited efficacy on the outcomes that matter clinically, the age-related decline itself has only been directly observed in a small number of human studies, and tissue-specific NAD+ dynamics remain understudied — calling for more rigorous clinical work rather than continued extrapolation from rodent data [18]. ## Reported cautions & open questions NAD+ and its precursors do not carry the same anecdotal community-report base as the other compounds on this desk, so this section draws on the documented controversies and open questions in the literature rather than user forum accounts. - **Oral NAD+ itself is poorly absorbed intact.** Most researchers consider the precursors NMN and NR the rational route for raising cellular NAD+; plain oral "NAD+" capsules are widely regarded as largely ineffective by comparison. - **Blood-level increases are well established; clinical-outcome translation is not.** The 2025 review above is explicit that human efficacy data remain limited [18]. - **IV NAD+ wellness therapy rests on minimal controlled evidence**, is marketed aggressively, and can cause chest or abdominal discomfort, flushing and nausea if infused too quickly; infused NAD+ is also cleared from plasma rapidly. - **Compounded injectable NAD+ carries contamination risk** — the FDA has issued a Class I recall of a compounded NAD+ injection over elevated bacterial endotoxin. - **A theoretical cancer-metabolism concern exists.** Because NAD+ supports the metabolism of proliferating cells generally, and its role in cancer biology is context-dependent, caution is generally advised for people in active cancer treatment. - **NMN's regulatory status is contested in the US** — the FDA has taken the position that NMN is excluded from the dietary-supplement category because it was previously investigated as a drug, creating marketplace uncertainty around how it can be labeled and sold. - **Supplement-grade product quality varies widely**, and third-party purity testing is not guaranteed across brands. ## Where it fits in Research Peptide Fundamentals NAD+ occupies a middle position on this desk: unlike [BPC-157](/bpc-157) or [ipamorelin](/ipamorelin), it has real dose-response human trial data; unlike [semaglutide](/semaglutide), that data has not yet been extended to a hard clinical outcome at scale. Its precursor-based delivery problem — the active molecule itself does not survive oral dosing intact — echoes a challenge [GHK-Cu](/ghk-cu) faces with skin penetration. See the [comparison page](/compare) for the full picture. --- A literature desk on five research peptides, read against the Canadian regulatory backdrop — not a clinic, not a vendor, not a prescription.